- Home
- Publications
- Publication Search
- Publication Details
Title
On the pharmacogenetics of non-small cell lung cancer treatment
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 12, Issue 3, Pages 307-317
Publisher
Informa Healthcare
Online
2016-01-14
DOI
10.1517/17425255.2016.1141894
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- International tailored chemotherapy adjuvant trial: ITACA trial.
- (2017) S. Novello et al. JOURNAL OF CLINICAL ONCOLOGY
- TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value
- (2016) Christophe Deben et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic
- (2015) Katerina Politi et al. CANCER CELL
- A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance
- (2015) M Dietel et al. CANCER GENE THERAPY
- Targeting cancer with kinase inhibitors
- (2015) Stefan Gross et al. JOURNAL OF CLINICAL INVESTIGATION
- Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non–Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial
- (2015) Jong-Mu Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers
- (2015) Ana I. Robles et al. Journal of Thoracic Oncology
- Role of circulating-tumor DNA analysis in non-small cell lung cancer
- (2015) Tao Jiang et al. LUNG CANCER
- Pharmacogenomics in the treatment of lung cancer: an update
- (2015) Daniela Morales-Espinosa et al. PHARMACOGENOMICS
- Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
- (2015) Niki Karachaliou et al. JAMA Oncology
- The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis
- (2014) Lei Wang et al. BMC CANCER
- The Expression of Four Genes as a Prognostic Classifier for Stage I Lung Adenocarcinoma in 12 Independent Cohorts
- (2014) H. Okayama et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC--Letter
- (2014) A. Avan et al. CLINICAL CANCER RESEARCH
- Pharmacogenetics in the Cancer Clinic: From Candidate Gene Studies to Next-Generation Sequencing
- (2014) H-J Guchelaar et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer
- (2014) Christian Rolfo et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to “Work it Out”?
- (2014) Elena Galvani et al. CURRENT PHARMACEUTICAL DESIGN
- On the use of pharmacogenetics in cancer treatment and clinical trials
- (2014) Jacques Robert et al. EUROPEAN JOURNAL OF CANCER
- Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer
- (2014) Maimon C. Rose et al. GENOMICS PROTEOMICS & BIOINFORMATICS
- Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
- (2013) Giuseppe Bronte et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
- (2012) Elena Galvani et al. CURRENT PHARMACEUTICAL DESIGN
- Polymorphisms to Predict Outcome to the Tyrosine Kinase Inhibitors Gefitinib, Erlotinib, Sorafenib and Sunitinib
- (2012) Lale Erdem et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Functional effect of polymorphisms in 15q25 locus on CHRNA5 mRNA, bulky DNA adducts andTP53mutations
- (2012) Xavier Tekpli et al. INTERNATIONAL JOURNAL OF CANCER
- Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin
- (2012) Marcello Tiseo et al. LUNG CANCER
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?
- (2012) Elisa Giovannetti et al. PHARMACOGENOMICS
- Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients
- (2011) C. Tibaldi et al. ANNALS OF ONCOLOGY
- Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer
- (2011) K Takezawa et al. BRITISH JOURNAL OF CANCER
- Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice
- (2011) Elisa Giovannetti et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Thymidylate synthase inhibitors for non-small cell lung cancer
- (2011) Elena Galvani et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Prospective Molecular Marker Analyses ofEGFRandKRASFrom a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer
- (2011) Wolfram Brugger et al. JOURNAL OF CLINICAL ONCOLOGY
- AKT1 polymorphisms and survival of early stage non-small cell lung cancer
- (2011) Min Jung Kim et al. JOURNAL OF SURGICAL ONCOLOGY
- Genome-Wide Association Study of Survival in Non–Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy
- (2011) Xifeng Wu et al. JNCI-Journal of the National Cancer Institute
- Gene Copy Number Aberrations Are Associated with Survival in Histologic Subgroups of Non-small Cell Lung Cancer
- (2011) Patrick Micke et al. Journal of Thoracic Oncology
- Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy
- (2011) Jong-Mu Sun et al. Journal of Thoracic Oncology
- Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed
- (2011) Chung-Yu Chen et al. LUNG CANCER
- Impact ofABCG2polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients
- (2011) Clara Lemos et al. PHARMACOGENOMICS
- Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer
- (2011) Y.-T. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reviewing the safety of erlotinib in non-small cell lung cancer
- (2010) Martin Reck et al. Expert Opinion On Drug Safety
- Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer: A North Central Cancer Treatment Group-Based Exploratory Study
- (2010) Araba A. Adjei et al. Journal of Thoracic Oncology
- Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib
- (2010) E. Giovannetti et al. MOLECULAR CANCER THERAPEUTICS
- Genome-wide association studies in pharmacogenomics
- (2010) Ann K. Daly NATURE REVIEWS GENETICS
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
- (2009) K. N. Syrigos et al. ANNALS OF ONCOLOGY
- Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib
- (2009) C Lemos et al. BRITISH JOURNAL OF CANCER
- Intracellular Trafficking of MDR Transporters and Relevance of SNPs
- (2009) Letizia Porcelli et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer
- (2009) C. M. Wright et al. EUROPEAN RESPIRATORY JOURNAL
- Pharmacogenomics of platinum-based chemotherapy in NSCLC
- (2009) Michelle AT Hildebrandt et al. Expert Opinion on Drug Metabolism & Toxicology
- Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non–Small-Cell Lung Cancer
- (2009) Egbert F. Smit et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426
- (2009) Alex A. Adjei et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib
- (2009) Fei Ma et al. LUNG CANCER
- Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers
- (2009) Marcello Tiseo et al. LUNG CANCER
- Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
- (2008) C Lemos et al. BRITISH JOURNAL OF CANCER
- EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
- (2008) J. P. Koivunen et al. CLINICAL CANCER RESEARCH
- Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity
- (2008) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
- (2008) Chin-Lun Huang et al. LUNG CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started